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Abstract: Azaspiracid-1 is an algal toxin that accumulates in edible mussels, and ingestion may
result in human illness as manifested by vomiting and diarrhoea. When injected into mice, it causes
neurotoxicological symptoms and death. Although it is well known that azaspiracid-1 is toxic to
most cells and cell lines, little is known about its biological target(s). A rat PC12 cell line, commonly
used as a model for the peripheral nervous system, was used to study the neurotoxicological effects
of azaspiracid-1. Azaspiracid-1 induced differentiation-related morphological changes followed by
a latter cell death. The differentiated phenotype showed peripherin-labelled neurite-like processes
simultaneously as a specific isoform of peripherin was down-regulated. The precise mechanism
behind this down-regulation remains uncertain. However, this study provides new insights into
the neurological effects of azaspiracid-1 and into the biological significance of specific isoforms
of peripherin.
Keywords: azaspiracid; algal toxin; neurotoxin; peripherin; intermediate filament; isoform;
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1. Introduction
The algal toxin azaspiracid-1 (AZA-1) was discovered in 1995 when it caused an outbreak
of diarrhetic shellfish poisoning (DSP)-like disease in humans. The symptoms included nausea,
vomiting, diarrhoea and stomach cramps [1]. Oral administration of AZA-1 to mice induced
histopathological changes of the intestine [2] and revealed a tumour promoting activity by
the toxin [3]. Unlike DSP-causing toxins, intraperitoneal injections of AZA-1 extracts in mice
produced neurological symptoms such as respiratory difficulties, spasms, paralysis and death [1,4].
Additionally, AZA-1 did not, unlike DSP-causing toxins, inhibit protein phosphatases 1 and 2A [5].
This led to the recognition that AZA-1 and its analogues produce a distinct disease named azaspiracid
shellfish poisoning [6].
AZA-1 is cytotoxic in the nanomolar range to a range of different mammalian cell types [5,7,8],
including neuroblastoma cells [7–9] and primary neurons [10–12]. The toxin is able to activate both
necrotic and apoptotic cell death pathways [8,11]. The c-Jun-N-terminal protein kinase (JNK) has
been shown to be implicated in AZA-1-induced neuronal cell death [13]. Two global studies, in which
changes in the transcriptome [14] and proteome [9] after AZA-1 treatment were studied, revealed that
AZA-1 induces changes in metabolic processes. However, the biological target of AZA-1 and its mode
of action still remain elusive.
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AZA-1 affects neuronal signalling in different cell types. The toxin is able to inhibit neurological
signalling in spinal cord neuronal networks, in young cerebellar granule cell cultures and in primary
neocortical neurons, and at high concentrations it acts as a hERG (human ether-à-go-go related gene)
channel blocker [11,12,15,16]. In a recent study, glutarylcarnitine, the main metabolite of glutaric acid,
was identified in azaspiracid-contaminated shellfish extracts [17]. Following this, Chevallier et al. [17]
showed that in the presence of glutaric acid, nanomolar concentration of AZA-1 could inhibit the
activity of sodium channels in vitro.
In mice orally exposed to AZA-1 the largest concentration of toxin was found in the
gastrointestinal tract [18]. Since AZA-1 has been shown to have a toxic effect on neuronal cells and
their derivatives [7–12], the enteric nervous system of the gastrointestinal tract might be a target for
the toxin. To further elucidate the neurotoxic effect of AZA-1 we have therefore used PC12 cells,
a cell line commonly used as a model for the enteric nervous system [19] and in studies focusing
on intestinal neuronal-epithelial interaction [20]. AZA-1 exposure induced an early differentiation
followed by cell death in PC12 cells. When elucidating markers known to be involved in PC12
differentiation, we found that AZA-1 specifically down-regulated an isoform of the neurospecific
intermediate filament protein peripherin. Peripherin is mainly expressed throughout the peripheral
nervous system, but it is also found in confined populations of neurons in the central nervous system,
particularly in neurons involved in motor function [21–25].
2. Results
2.1. AZA-1 Induces Morphological Alterations in PC12 Cells
In our initial dose-response experiments, PC12 cells exposed to 15 nM showed a significant
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Figure 1. Co centration-dependent effect of AZA-1 o 12 cell viability. PC12 cells were exposed
to increasing dosages of AZA-1 o correspo ding solvent control. Cell viability was d termined by
CCK-8 assay. Values are the mean ˘ SD (n = 2–3).
Further experiments w re therefore using 15 nM AZA-1 or solvent contr l for 24–72 h.
AZA-1-exposed cells had a more rounde ology and neurite-like outgrowths when compared
to control cells (Figure 2A,B).
Approx. 17% of the AZA-1-treated cells were scored positive for neurite-like outgrowths
(Figure 2B). However, at 48 h of exposure, the viability and cell number in AZA-1-treated cells were
reduced, although some cells seemed to survive AZA-1 treatment (Figure 2C,D).
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Since  AZA‐1‐exposed  cells  appeared  more  differentiated  compared  to  control  cells,  we 
elucidated the expression of the PC12‐associated neuronal differentiation marker, peripherin [26]. In 
untreated cells, peripherin was observed in patches of the whole cell with little specific organisation 
or  filament  structures  (Figure  3A–C).  In  cells  exposed  to  AZA‐1,  neurite‐like  protrusions  with 
condensed bundles of peripherin filaments were frequently observed (Figure 3E–G) and mean cell 
fluorescence was  increased  compared  to  control  (Figure  3D).  Furthermore, AZA‐1‐exposed  cells 
showed more condensed labelling of peripherin in close proximity to the nucleus. 
Figure 2. Effect of AZ -1 on PC12 morphology and cell viability. PC12 cells were treated with 15 nM
AZA-1 for 6 h to 72 h, or negative control. (A) Cell morphology after AZA-1 exposure. AZA-treated
cells appeared more differentiated with neurite-like protrusions compared to controls. Bar, 20 µm.
(B) Quantitation of neurite-like protrusions. C.d. = cell diameter. (C) Cell viability as determined
based on dehydrogenase activity using CCK-8 assay. Data are presented as mean ˘ SD (n = 9) of
three independent experiments. Statistical analysis was performed using one-way ANOVA followed
by Tukey’s post hoc test (* p < 0.01). (D) Reduction of cell number after AZA-1 exposure. Data are
shown as mean ˘ SD (n = 3).
2.2. AZA-1 Down-Regulates a Specific Peripherin Isoform
Since AZA-1-exposed cells appeared more differentiated compared to control cells, we elucidated
the expression of the PC12-associated neuronal differentiation marker, peripherin [26]. In untreated
cells, peripherin was observed in patches of the whole cell with little specific organisation or filament
structures (Figure 3A–C). In cells exposed to AZA-1, neurite-like protrusions with condensed
bundles of peripherin filaments were frequently observed (Figure 3E–G) and mean cell fluorescence
was increased compared to control (Figure 3D). Furthermore, AZA-1-exposed cells showed more
condensed labelling of peripherin in close proximity to the nucleus.
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The differentiation‐inducing  effect  of AZA‐1 was  also  tested  by  analysing  the  effect  on  the 
neuronal markers tyrosine hydroxylase and tubulinβ3 [29]. Tyrosine hydroxylase showed an early 
transient  increase after AZA‐ exposure  (Figure 4C), whilst  little effect was observed on  tubulin3 
(Figure 4B). 
 
Figure  4.  Time‐dependent  effect  of  AZA‐1  on  the  neuronal  differentiation  markers  peripherin, 
tubulinβ3, and tyrosine hydroxylase. Cells were exposed to 15 nM AZA‐1 or negative control for up 
to 24 h and differentiation marker expression was analysed by Western blotting. (A) Three peripherin 
Figure 3. Neurite-like protrusions are strongly stained with peripherin. AZA-1 exposed (15 nM, 24 h)
PC12 cells (E-I) and controls (A-C) were processed for immuno- abelling using anti-perip erin (red).
Panel D shows relative mean cell fluorescence ˘ sem (n = 30). Panel H/I show negative control with
no primary antibody added. Nuclei were stained with DAPI (blue).
The peripherin filaments observed in the protrusions further support the possibility that AZA-1
triggers a differentiation process, as peripherin is known to label neurites in differentiated PC12
cells [27].
To observe possible changes in peripherin isoform levels after AZA-1 exposure cell lysates
were analysed by Western blotting. The peripherin antibody used recognised three different bands,
ranging from 50 to 60 kDa (Figure 4A). This is in accordance with Robertson et al. [28] who used the
same antibody.
The differentiation-inducing effect of AZA-1 was also tested by analysing the effect on the
neuronal markers tyrosine hydroxylase and tubulinβ3 [29]. Tyrosine hydroxylase showed an early
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Figure 4. Time-dependent effect of AZA-1 on the neuronal differentiation markers peripherin,
tubulinβ3, and tyrosine hydroxylase. Cells were exposed to 15 nM AZA-1 or negative control for up
to 24 h and differentiation marker expression was analysed by Western blotting. (A) Three peripherin
bands were observed whereas the second band (indicated by an asterisk) was down-regulated at all
examined time points after addition of AZA-1; (B) The blot was then stripped and reprobed with
anti-tubulinβ3; (C) Tyrosine hydroxylase expression. PonS stainings (A,B) and (C) are shown as
loading control.
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It is well known that intermediate filaments are not always soluble in CHAPS detergent, which
was used in the lysis buffer [30]. To ensure that the down-regulated peripherin isoform did not
remain in the CHAPS-insoluble fraction, the pellet was also analysed by Western blotting (Figure 5).













treated  with  15  nM  AZA‐1or  solvent  control  for  24  h  and  lysed  in  homogenisation  buffer.   












1 2 3  4  5 
149032092  Peripherin, isoform CRA_a  506  x         
129822  Peripherin  468  x    x  x  X 
149032093  Peripherin, isoform CRA_b  474    x       
GI: GenInfo identifier. #: Gel band number as in Figure 6A. 
In addition to identifying the known main variant of rat peripherin protein (GI: 129822; hereafter 
called  Pe‐58  in  accordance  with  the  naming  of  peripherin  isoforms  in  mouse  [31]),  previously 
predicted  peripherin  isoforms were  also  found  (Figure  6B–F,  Table  1,  Supplementary Materials 
Tables S1–S5). 
Particularly  interesting was  the  identification  of peripherin  isoform CRA_a  (GI:  149032092).   
This isoform was found exclusively in band #1 (Figure 6A,E). In this isoform, intron four is retained, 





Figure 5. The down-regulated peripherin isofo is not found in the insoluble fraction. Cells w re
treated with 15 nM AZA-1or solvent control for 24 h and lysed in homogenisation buffer. The
insoluble pellet obtained after centrifugation was dissolved in SDS-containing sample buffer. Western
blot analysis with peripherin antibody showed that the second peripherin band disappeared both in
the soluble and insoluble fraction after AZA-1 treatment. PonS staining was used as loading control.
Molecular weight in kDa.
2.3. Mass Spectrometry-Based Verification of Peripherin Isoforms
To confirm that the down-regulated band observed by Western blotting was peripherin, mass
spectrometry was utilised. Proteins were separated by SDS-PAGE and bands corresponding to
peripherin were excised and analysed by mass spectrometry (Figure 6A). Peripherin was identified
in all five gel slices (Table 1), further supporting that the down-regulated band was peripherin.
Table 1. Peripherin isoforms identified in gel bands.
GI Protein Name No of Amino Acids
Band #
1 2 3 4 5
149032092 Peripherin, isoform CRA_a 506 x
129822 Peripherin 468 x x x X
149032093 Peripherin, isoform CRA_b 474 x
GI: GenInfo identifier. #: Gel band number as in Figure 6A.
In addition to identifying the known main variant of rat peripherin protein (GI: 129822;
hereafter called Pe-58 in accordance with the naming of peripherin isoforms in mouse [31]),
previously pre icted peripherin isoforms were also found (Figure 6B–F, Tabl 1, Supplementary
Materials Tables S1–S5).
Particularly interesting was the identification of peripherin isoform CRA_a (GI: 149032092).
This isoform was found exclusively in band #1 (Figure 6A,E). In this isoform, intron four is retained,
giving rise to a 32-amino-acid-long insert in the protein sequence and hence an increased mass
compared to Pe-58 (Figure 6C). This alternatively spliced isoform is known in mouse as Pe-61 [31,32];
however, to our knowledge, it has not been previously identified in rat. Additionally, we identified
CRA_b (GI: 149032093) in band #2 (Figure 6A,F). In this isoform the first in-frame start codo is used,
giving ris to six additional N-terminal amino acids (Figure 6D).
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exist  in  rats. Note  that  isoform  CRA_a/Pe‐61  uses  the  first  in‐frame  start  codon,  resulting  in  6 
Figure 6. Identification of peripherin isoforms by mass spectrometry. (A) Proteins from total cell
lysates (15 nM AZA-1 or negative control) were separated by SDS-PAGE. The gels were ither further
processed for analysis by Western blotting using a peripherin antibody or stained with Coomassie.
The Western blot was used as guidance for excision of five gel slices (from the control lysate) of the
Coomassie-stained gel. Th proteins in the gel slic s were in-gel digested and analysed by mass
spectrometry. Peripherin isoforms were identified in all five gel slices (see Table 1). (B) Structure of
the rat peripherin gene (ENSRNOG00000015643; 1 September 2014). The gene consists of 9 exons,
labelled 1–9. Grey areas indicate protein-coding sequences. There are two start codons in-frame
with the longest open reading frame, of which the second (ATG2) is considered the canonical start
codon. Normally all introns are spliced out to give rise to peripherin. Dotted black lines indicates a
possible alternative splicing event in which intron 4 (I4) is retained, giving rise to a 96-bp-long insert
between exon 4 and exon 5 in the mature mRNA. This spli i g event has previously b en shown to
take place in mouse peripherin mRNA and is named Pe-61. (C) The two possible mRNAs resulting
from the splicing events described in (B). Retention of I4 gives rise to a 32 amino acid long insert
(underlined in black in the protein sequence). A tryptic peptide unique for the peripherin isoform
CRA_a/Pe-61 which is identified by mass spectrometry is labelled in red. As can be seen, parts of
intron 4 connected to exon 5 was identified with the mass spectrometer, indicating that this isoform
of peripherin does exist in rats. Note that isoform CRA_a/Pe-61 uses the first in-frame start codon,
resulting in 6 additional amino acids on its N-terminal and hence a different numbering of the amino
acids. (D) The N-terminal amino acid sequence of peripherin and the predicted peripherin isoform
CRA_b, in which the first in-frame start codon is used. Our mass spectrometry data identified a
tryptic peptide containing five of the six most N-terminal amino acids in peripherin isoform CRA_b.
(E) Mass spectrum of the tryptic peptide consisting of parts of intron 4 connected to exon 5 in
peripherin isoform CRA_a/Pe-61. (F) Mass spectrum of the N-terminal tryptic peptide in peripherin
isoform CRA_b.
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The question remains as to which isoform is down-regulated by AZA-1 exposure. It is tempting
to assume that the most intense band on the Western blot (Figures 4A and 6A) represents the Pe-58
isoform as it runs as a ~58 kDa protein, which is in good accordance with previous reports [31,32].
In addition, Pe-58 is the constitutively expressed isoform, making it reasonable that it represents the
most intense band. This would imply that the identified isoform CRA_a/Pe-61 is not detected with
the antibody used in this study, possibly due to amounts below the detection limit [28]. In mice,
a third peripherin isoform, which runs on SDS-polyacrylamide gels as a 56 kDa protein, has been
described [31,32]. This would fit well with the observed molecular weight of the down-regulated
peripherin isoform in our study.
2.4. Peripherin is Not Down-Regulated at the Transcriptional Level
We then tested whether AZA-1-induced peripherin down-regulation could be assigned to the
transcriptional level. PC12 cells were treated with 15 nM AZA-1 for 24 or 48 h or with negative
control, and reverse transcriptase-PCR was used to examine relative expression levels. The forward
primer located at the exon four–exon five junction and reverse primer located in exon nine were used
to detect peripherin. This primer pair would recognise both Pe-58 and a potential Pe-56 variant if it
exists in rats (the Pe-61 variant would not be detected using this primer pair, but we had already
excluded it as being the down-regulated band due to its larger size). One band at the expected
size for Pe-58 was detected, but no regulation of the expression of peripherin mRNA was observed
(data not shown).
2.5. Peripherin Down-Regulation Is Not Dependent on the Proteasome, Caspases and Calpains
The peripherin isoform is completely disappeared within three hours after AZA-1 administration.
Since the half-life of peripherin is 33 h [27], this rapid and complete down-regulation indicates a
degradation/cleavage of the protein rather than a down-regulation of the mRNA. We therefore
tested if the down-regulated peripherin isoform was degraded by the proteasome system. However,
inhibition of the proteasome did not prevent the observed disappearance of the peripherin isoform
after AZA-1 treatment (Figure 7). Interestingly, pre-incubation with the proteasome inhibitor by
itself also led to disappearance of the peripherin isoform, even in the absence of AZA-1 treatment.
Furthermore, it was noted that the morphology of MG132-treated cells resembled the morphology
of AZA-1-treated cells, with neurite-like protrusions occurring (data not shown). Since AZA-1 and
MG132 produced similar effects, we checked if AZA-1 acted as a proteasome inhibitor by assessing
the degree of protein ubiquitination after AZA-1 exposure. Pre-incubation with MG132 increased the
overall levels of ubiquitination as expected, but AZA-1 treatment did not result in any accumulation
of protein ubiquitination (data not shown), indicating that AZA-1 did not inhibit the proteasome.
We examined if peripherin was degraded by apoptosis-associated caspases as it has previously
been shown that AZA-1 activated caspases in a number of different cell types [8,11]. However,
pre-incubation with the broad caspase inhibitor Z-VAD-FMK did not prevent down-regulation of
the peripherin isoform after AZA-1 treatment (Figure 7).
Kim et al. have recently identified peripherin as a novel calpain target [33]. Furthermore,
calpains are Ca2+-dependent [34] and AZA-1 treatment has been shown to elevate intracellular
calcium levels [10], but no calpain inhibitor effect was observed (Figure 7).
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AZA‐1 exposure. Cells were pre‐incubated  for 1 h with a proteasome  inhibitor  (MG132),  caspase 
inhibitor (Z‐VAD‐FMK) or calpain inhibitor (PD150606) prior to exposure to 15 nM AZA‐1 or negative 
control for 24 h. Expression of peripherin isoforms (arrows) was detected using Western blotting. Pre‐










exposure  to AZA‐1 decreased cell viability, a more differentiated phenotype was observed  in  the 
early stage after toxin addition. The differentiated cellular phenotype with neurite‐like protrusions 
was observed simultaneously with the change in peripherin isoform stoichiometry. 
Peripherin  is  mainly  expressed  in  the  peripheral  nervous  system  [25,35]  and  found  in 
pathological  inclusions of patients with amyotrophic  lateral  sclerosis  (ALS)  [36].  It has also been 
shown that peripherin isoform expression profiles are altered in ALS and after neuronal injury [37]. 
The functional relevance of the different isoforms is not known, but when expressed in SW13 vim (−),   
a cell  line  lacking cytoplasmic  intermediate  filament proteins, distinct morphologies and  filament 
assembly are observed  [28,38]. Transgenic mice over‐expressing peripherin  show  selective motor 
neuron degeneration [39]. On the other hand, up‐regulation of peripherin is observed after neuronal 
injury  [37,40]  and  has  been  shown  to  be  cytoprotective  [41],  further  supporting  that  specific 
peripherin isoform expression may have individual roles. 
Although we  cannot be  sure of  the  identity of  the down‐regulated peripherin  isoform,  it  is 
tempting to believe that it is homologous to the mouse Pe‐56 isoform [31,32]. This fits well with the 
molecular weight  observed  and  expression  level  compared  to  the main  constitutively  expressed 
isoform Pe‐58. Pe‐56 has been shown to be down‐regulated in response to a low level of oxidative 
stress  in  mouse  neuroblastoma  cells,  although  at  higher  levels  of  oxidative  stress  Pe‐56  levels 










Figure 7. The proteasome, caspases and calpains are not involved in peripherin down-regulation
after AZA-1 exposure. Cells were pre-incubated for 1 h with a proteasome inhibitor (MG132), caspase
inhibitor (Z-VAD-FMK) or calpain inhibitor (PD150606) prior to exposure to 15 nM AZA-1 or negative
control for 24 h. Expression of peripherin isoforms (arrows) was detected using Western blotting.
Pre-incubation with the different inhibitors did not prevent down-regulation of the second peripherin
band (indicated by an asterisk). It was noted that pre-treatment with the proteasome inhibitor MG132
alone also led to a down-regulation of the second peripherin band (third lane from left).
3. Discussion
Exposure to the algal toxin AZA-1 has shown to induce neurotoxicological symptoms [1,4], and
a number of studies have been performed on neuronal cells [10–12] and their derivatives [7–9], but its
biological target is still not known. In this study we have used PC12 cells. This cell line is commonly
used as a model for the enteric nervous system [19], by which oral exposure to the toxin will be the
first part of the neuronal system to be reached. We here show that AZA-1 down-regulates a specific
isoform of the intermediate filament protein peripherin in PC12 cells. Although long-term exposure
to AZA-1 decreased cell viability, a more differentiated phenotype was observed in the early stage
after toxin addition. The differentiated cellular phenotype with neurite-like protrusions was observed
simultaneously with the change in peripherin isoform stoichiometry.
Peripherin is mainly expressed in the peripheral nervous system [25,35] and found in
pathological inclusions of patients with amyotrophic lateral sclerosis (ALS) [36]. It has also been
shown that peripherin isoform expression profiles are altered in ALS and after neuronal injury [37].
The functional relevance of the different isoforms is not known, but when expressed in SW13
vim (´), a cell line lacking cytoplasmic intermediate filament proteins, distinct morphologies and
filament assembly are observed [28,38]. Transgenic mice over-expressing peripherin show selective
motor neuron degeneration [39]. On the other hand, up-regulation of peripherin is observed after
neuronal injury [37,40] and has been shown to be cytoprotective [41], further supporting that specific
peripherin isoform expression may have individual roles.
Although we cannot be sure of the identity of the down-regulated peripherin isoform, it is
tempting to believe that it is homologous to the mouse Pe-56 isoform [31,32]. This fits well with
the molecular weight observed and expression level compared to the main constitutively expressed
isoform Pe-58. Pe-56 has been shown to be down-regulated in response to a low level of oxidative
stress in mouse neuroblastoma cells, although at higher levels of oxidative stress Pe-56 levels
remained at control level [42]. In our hands, AZA-1 did not induce oxidative stress as judged by
oxyblotting towards protein carbonylation (data not shown). This is in accordance with Vale et al. [10],
who showed that AZA-1 did not increase oxidative stress using a reactive oxygen species sensitive
fluorescent probe. Thus, the down-regulation of Pe-56 may not necessarily be directly coupled to
oxidative stress.
We observed a concomitant down-regulation of a specific peripherin isoform and increased
cell differentiation with peripherin filament assembly in neurite-like protrusions following AZA-1
exposure of PC12 cells. Previous studies have shown peripherin expression to be necessary for PC12
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cells to form neuritic processes upon differentiation induced by nerve growth factor [27]. Overall,
this indicates that the presence of Pe-56 is not essential in the developing neurites.
We checked if peripherin was degraded by caspases or calpains, both involved in apoptosis,
but peripherin isoform down-regulation does not appear to be mediated through these proteases.
A possible degradation of peripherin isoform by the proteasome system was explored by using
proteasome inhibitor MG132. Down-regulation of peripherin isoform was not prevented, but we
observed that MG132 and AZA-1 both induced down-regulation of the same peripherin isoform and
a similar differentiated morphological appearance [43]. Also, in a recent study on the effect of the
proteasome inhibitor lactacystin on PC12 cells, peripherin was identified to be down-regulated by
this proteasome inhibitor [44]. However, the authors did not show which isoform is down-regulated
or what the mechanism behind this down-regulation might be. It is rather puzzling that proteasome
inhibition would lead to peripherin down-regulation. However, MG132 has been shown to have
several targets in the cells in addition to being a proteasome inhibitor [43,45–47].
Dysregulation of peripherin and its splice variants has been associated with the
neurodegenerative disease ALS [28,37,38,48]. Therefore, the fact that an algal toxin specifically
down-regulates a peripherin isoform may provide a new tool for understanding the relevance of
peripherin in neuronal cell death.
In conclusion, we have shown that exposure to AZA-1 induces an early differentiated
phenotype followed by later cell death in PC12 cells. The differentiated appearance coincides with
down-regulation of a specific peripherin isoform, a neuronal specific intermediate filament protein.
4. Experimental Section
All chemicals were from Sigma-Aldrich unless otherwise stated.
4.1. Cell Culturing and Treatment
Rat adrenal pheochromocytoma PC12 cells were cultured as previously described in [49].
Cells were seeded to obtain a confluency of around 70% at the time of exposure to 15 nM AZA-1
(cat. No. CRM-AZA1, National Research Council, ON, Canada) or solvent control (DMSO). The
following inhibitors were used: 1 µM proteasome inhibitor MG132 (#C2211, Sigma-Aldrich, St. Louis,
MO, USA),; 100 µM caspase inhibitor Z-VAD-FMK (#FMK001, R&D Systems, Minneapolis, MN,
USA); 100 µM calpain inhibitor PD150606 (#D5946, Sigma-Aldrich, St. Louis, MO, USA).
4.2. Evaluation of Cell Morphology and Viability
Measurement of neurite-like outgrowth was performed on micrographs taken of live cells by
manually measuring outgrowth length compared to perikaryon diameter. Outgrowths were counted
as “neurite-like” if outgrowth lengths were more than 0.5 times of perikaryon diameter. At least
130 cells from three fields per well were evaluated.
Cell viability was measured using Cell Counting Kit-8 (CCK-8)( Sigma-Aldrich, St. Louis,
MO, USA) according to the manufacturer’s protocol. PC12 cells were seeded in 96-well plates
(30,000 cells/well) 24 h before treatment with or without AZA-1. Attached cells were trypsinated
and counted together with detached cells using a Neubauer chamber.
4.3. Immunofluorescence
Cells (220,000 cells/well) were seeded on poly-L-Lysine coated cover slips in a 24-well plate
one day prior to exposure to 15 nM AZA-1 or solvent control for 24 h. Cells were prepared
for immunofluorescence staining as previously described [9] using anti-peripherin (1:400, AB1530,
Millipore, Billerica, MA, USA) and AlexaFluor594 anti-rabbit (1:200A11012, ThermoFisher, Waltham,
MA, USA). Nuclei were stained using DAPI. Images were captured with a Zeiss LSM 510 META
confocal microscope (Zeiss, Oberkochen, Germany). Cell fluorescence was quantitated using ImageJ
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version 1.47 according to the formula: Corrected total cell fluorescence = Integrated density—(area of
selected cell x mean fluorescence of background readings).
4.4. SDS-PAGE and Western Blotting
Cells were lysed in homogenisation buffer (10 mM K2HPO4, 10 mM KH2PO4, 1 mM EDTA,
0.6% (w/v) 3-((3-cholamidopropyl)dimethylammonio)-1-propanesulfonate (CHAPS), 0.2 mM
Na3VO4, 50 mM NaF, Complete Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim,
Germany)and cleared by centrifugation. For analysis of the insoluble fraction, the pellet after
centrifugation was dissolved in 100 µL SDS sample buffer and 20 µL loaded. Proteins separated
on 8% SDS-polyacrylamide gels were either stained with Coomassie or transferred to PDVF
membranes (RPN303F, GE Healthcare, Buckinghamshire, UK). Membranes were blocked in 1% BSA
in PBS-Tween for one hour. Membranes were incubated with anti-peripherin rabbit polyclonal
antibody (Millipore, Billerica, MA, USA AB1530, 1:1000), anti-betaTubulin3 mouse monoclonal
antibody (Santa Cruz, Dallas, TX USA sc-51670, 1:500), or anti-tyrosine hydroxylase mouse
monoclonal antibody (SigmaAldrich, St. Louis, MO, USA, T2928, 1:1000) for one h at RT, followed
by peroxidase-conjugated anti-rabbit or anti-mouse antibodies (Jackson ImmunoResearch, West
Baltimore Pike, West Grove,PA, USA, 1:10,000, 1 h at RT). Blots were developed with one mL ECL
solution (ThermoFisher, Waltham, MA, USA) using a ChemiDoc™ (Bio-Rad, Hercules, CA, USA).
Washing with PBS-T (3 ˆ 10 min) was performed between all incubation steps. In all gels used for
Western blotting, 40 µg protein was loaded per well. Ponceau-S staining was used as loading control.
4.5. RNA Isolation and Reverse Transcription
Total RNA from PC12 cells were extracted with Trizol (ThermoScientific, Waltham, MA, USA)
according to the manufacture instruction. RNA concentration and quality was assed using
NanoDrop ND1000 (ThermoScientific, Waltham, MA, USA). To synthesize cDNA, Oligo dT primer
and Transcriptor reverse transcriptase (Roche, Basel, Switzerland) was used. To detect the
transcriptional level of Pe-58 and Pe-56, 500 ng cDNA was amplified by PCR using forward primer
51-AAGAAGCTACACGAAGAGGAG-31 and reverse primer 51-GGAGGGTTCGAGCTTAGGAA-31.
4.6. Identification of Peripherin Isoforms
A Western blot was compared to a Coomassie-stained protein gel and bands were excised
manually from the gel. Proteins were in-gel digested with trypsin (V5111, Promega, Madison, WI,
USA) and peptides were extracted and reduced/alkylated according to Kellmann et al. [9]. Mass
spectrometry analysis was performed according to [50], with the following modifications: the 15 ions
with highest intensity were sequenced, normalized collision energy was 35%, dynamic exclusion
was 30 s.
4.7. Data Analysis
Raw data were converted to mgf files with Proteome discoverer™ software version 1.3
(ThermoScientific, Waltham, MA, USA) and searched against NCBInr (2012.04.15; taxonomy
Rattus, 67,662 sequences) using Mascot Daemon version 2.3.0 (Matrix Science, Boston, MA, USA)
and the Mascot search engine (http://www.matrixscience.com). Fixed modification was
carbamidomethylated cysteines, whereas variable modifications were oxidised methionine,
nitrosylated tyrosine and phosphorylated serine, threonine and tyrosine. Mass tolerance for MS and
MS/MS was set to 10 ppm and 0.6 Da respectively, and maximum allowed missed cleavages were
two. Proteins were identified with a significant threshold of p < 0.05 at peptide level.
Supplementary Materials: See Supplementary Materials Tables S1–S5.
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